文献速递药物相互作用治疗药物监测与药物基因组学特殊人群用药

利福平与长效卡博特韦/利匹韦林相互作用快速发生与消退:一例药代动力学病例报告

Rapid onset and offset of the interaction between rifampicin and long-acting cabotegravir/rilpivirine: A pharmacokinetic case report.
PubMed 文献 · Br J Clin Pharmacol · 2026-09-27

一例病毒学抑制的HIV-1感染者接受每8周一次长效肌注卡博特韦/利匹韦林期间,因MRSA根除治疗使用利福平600mg每日两次共7天,同时口服桥接替诺福韦/恩曲他滨和多替拉韦。利福平治疗7天后卡博特韦和利匹韦林血浆浓度分别下降57%和83%,利匹韦林低于治疗目标;停药1周后浓度恢复。

要点

  • 利福平与长效卡博特韦/利匹韦林联用可快速降低两者血浆浓度,利匹韦林降幅更大。
  • 利福平治疗7天后利匹韦林浓度低于 proposed 治疗目标,卡博特韦仍高于目标。
  • 停药后浓度自行恢复,反映肌注储库持续释放,HIV-1 RNA全程检测不到。

核心结论

  • 利福平与长效肌注卡博特韦/利匹韦林联用可快速降低卡博特韦和利匹韦林血浆浓度,利匹韦林降幅超过既往生理药代动力学模型预测。

研究设计与样本

  • 单例49岁病毒学抑制的HIV-1感染男性病例报告,接受每8周一次长效肌注卡博特韦/利匹韦林。

主要发现

  • 利福平600mg每日两次治疗7天后,卡博特韦浓度从2.08 mg/L降至0.90 mg/L(降57%),利匹韦林从0.126 mg/L降至0.022 mg/L(降83%),利匹韦林低于 proposed 治疗目标。
  • 利福平停药1周后卡博特韦恢复至1.10 mg/L、利匹韦林恢复至0.050 mg/L,后续无额外给药浓度继续上升。
  • 随访期间HIV-1 RNA持续检测不到。

关键数值与推荐

  • 利福平开始前卡博特韦和利匹韦林浓度分别为2.08 mg/L和0.126 mg/L,均高于目标Ctrough(卡博特韦>0.664 mg/L,利匹韦林>0.032 mg/L)。

临床怎么用

  • 长效卡博特韦/利匹韦林禁与利福平联用;短期酶诱导需桥接口服抗逆转录病毒治疗并监测血药浓度。

局限性

  • 单例病例报告,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Long-acting intramuscular cabotegravir/rilpivirine (LA CAB/RPV) is contraindicated with rifampicin because of the risk of markedly reduced antiretroviral exposure, although clinical pharmacokinetic data for this interaction are lacking. We describe a 49-year-old man with virologically suppressed HIV-1 infection receiving LA CAB/RPV every 8 weeks who was treated with rifampicin 600 mg twice daily combined with levofloxacin for 7 days as methicillin-resistant Staphylococcus aureus eradication therapy. Temporary oral bridging therapy with tenofovir disoproxil fumarate/emtricitabine and dolutegravir was started concurrently. Plasma cabotegravir (CAB) and rilpivirine (RPV) concentrations were measured weekly using validated LC-MS/MS. Prior to rifampicin initiation, plasma concentrations were 2.08 mg/L for CAB and 0.126 mg/L for RPV and therefore well above target Ctrough levels of >0.664 mg/L for CAB and >0.032 mg/L for RPV. After 7 days of rifampicin treatment, concentrations decreased to 0.90 mg/L for CAB and 0.022 mg/L for RPV, corresponding to reductions of 57% and 83%, respectively, with RPV concentrations falling below the proposed therapeutic target. One week after rifampicin discontinuation, concentrations recovered to 1.10 mg/L for CAB and 0.050 mg/L for RPV. The concentrations increased further thereafter without additional drug administration, reflecting continued release from the intramuscular depot. HIV-1 RNA remained undetectable throughout follow-up. The observed reduction in RPV exposure exceeded previous physiologically based pharmacokinetic model predictions for intramuscular RPV. This case provides a pharmacokinetic rationale for more nuanced management of short-term enzyme induction in people with HIV receiving LA ART and may help inform future clinical guidance.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Gieling EM, Bevers LAH, Smit WL, et al. Rapid onset and offset of the interaction between rifampicin and long-acting cabotegravir/rilpivirine: A pharmacokinetic case report. Br J Clin Pharmacol. 2026. PMID: 42802558. doi:10.1002/bcp.70856

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。